US35104E1001 - FDMT (XNAS)
4D MOLECULAR THERAPEUTICSCS INC Aktie
13,50 USD
Aktuelle Kurse von 4D MOLECULAR THERAPEUTICSCS INC
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NASDAQ |
FDMT
|
USD
|
19.09.2024 23:02
|
13,50 USD
| 16,82 USD | -19,74 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | -16,92 % | -5,53 % | -40,74 % | -57,84 % | -9,88 % | -66,67 % |
Firmenprofil zu 4D MOLECULAR THERAPEUTICSCS INC Aktie
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Unternehmensdaten zur 4D MOLECULAR THERAPEUTICSCS INC Aktie
Name 4D MOLECULAR THERAPEUTICSCS INC
Firma 4D Molecular Therapeutics, Inc.
Symbol FDMT
Heimatbörse
NASDAQ
ISIN US35104E1001
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dr. David H. Kirn M.D.
Marktkapitalisierung 780 Mio
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,2 T
Adresse 5858 Horton Street, 94608 EmeryVille
IPO Datum 2020-12-11
Ticker Symbole
Name | Symbol |
---|---|
NASDAQ | FDMT |
Weitere Aktien
Investoren die 4D MOLECULAR THERAPEUTICSCS INC halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024